Barclays’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
Other funds holding AKBA
Barclays's AKBA Position: Q3 2026 in Review
Barclays increased its Akebia Therapeutics (AKBA) stake by 21% in Q3 2026, buying an estimated $29K and bringing the position to 155,290 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #4159.
Barclays first reported a position in AKBA in Q2 2014 and has held it in 43 quarters since. The position peaked at $3.58M in Q2 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.
- Barclays held 155,290 shares of Akebia Therapeutics worth $143K as of Q3 2026.
- Barclays bought 26,932 Akebia Therapeutics shares in Q3 2026, an estimated $29K.
- Akebia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4159 holding.
- Barclays first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 43 quarters since.
- Barclays's Akebia Therapeutics position peaked at $3.58M in Q2 2025.
- 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.